537 related articles for article (PubMed ID: 23942540)
1. Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
Contin M; Albani F; Riva R; Candela C; Mohamed S; Baruzzi A
Ther Drug Monit; 2013 Dec; 35(6):849-52. PubMed ID: 23942540
[TBL] [Abstract][Full Text] [Related]
2. Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs.
Markoula S; Teotonio R; Ratnaraj N; Duncan JS; Sander JW; Patsalos PN
Ther Drug Monit; 2014 Aug; 36(4):494-8. PubMed ID: 24562047
[TBL] [Abstract][Full Text] [Related]
3. Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
Contin M; Albani F; Riva R; Baruzzi A
Ther Drug Monit; 2004 Aug; 26(4):375-9. PubMed ID: 15257066
[TBL] [Abstract][Full Text] [Related]
4. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
Contin M; Riva R; Albani F; Avoni P; Baruzzi A
Ther Drug Monit; 2002 Jun; 24(3):332-7. PubMed ID: 12021622
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Drug Monitoring of Lacosamide in Norway: Focus on Pharmacokinetic Variability, Efficacy and Tolerability.
Svendsen T; Brodtkorb E; Baftiu A; Burns ML; Johannessen SI; Johannessen Landmark C
Neurochem Res; 2017 Jul; 42(7):2077-2083. PubMed ID: 28349359
[TBL] [Abstract][Full Text] [Related]
6. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
7. Synergism of lacosamide with established antiepileptic drugs in the 6-Hz seizure model in mice.
Shandra A; Shandra P; Kaschenko O; Matagne A; Stöhr T
Epilepsia; 2013 Jul; 54(7):1167-75. PubMed ID: 23750855
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive lacosamide in clinical practice: sodium blockade with a difference?
Stephen LJ; Kelly K; Parker P; Brodie MJ
Epilepsy Behav; 2011 Nov; 22(3):499-504. PubMed ID: 21890421
[TBL] [Abstract][Full Text] [Related]
9. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
Gidal BE; Ferry J; Majid O; Hussein Z
Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
[TBL] [Abstract][Full Text] [Related]
10. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication.
Johannessen Landmark C; Baftiu A; Tysse I; Valsø B; Larsson PG; Rytter E; Johannessen SI
Ther Drug Monit; 2012 Aug; 34(4):440-5. PubMed ID: 22777154
[TBL] [Abstract][Full Text] [Related]
12. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
[TBL] [Abstract][Full Text] [Related]
13. A high-performance liquid chromatography assay to monitor the new antiepileptic drug lacosamide in patients with epilepsy.
Greenaway C; Ratnaraj N; Sander JW; Patsalos PN
Ther Drug Monit; 2010 Aug; 32(4):448-52. PubMed ID: 20386357
[TBL] [Abstract][Full Text] [Related]
14. Influence of Dose and Antiepileptic Comedication on Lacosamide Serum Concentrations in Patients With Epilepsy of Different Ages.
May TW; Helmer R; Bien CG; Brandt C
Ther Drug Monit; 2018 Oct; 40(5):620-627. PubMed ID: 30086089
[TBL] [Abstract][Full Text] [Related]
15. Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication.
May TW; Rambeck B; Neb R; Jürgens U
Ther Drug Monit; 2007 Dec; 29(6):789-94. PubMed ID: 18043477
[TBL] [Abstract][Full Text] [Related]
16. Comparison of lacosamide concentrations in cerebrospinal fluid and serum in patients with epilepsy.
May TW; Brandt C; Helmer R; Bien CG; Cawello W
Epilepsia; 2015 Jul; 56(7):1134-40. PubMed ID: 25988882
[TBL] [Abstract][Full Text] [Related]
17. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy.
Contin M; Riva R; Albani F; Baruzzi AA
Ther Drug Monit; 1999 Dec; 21(6):604-8. PubMed ID: 10604819
[TBL] [Abstract][Full Text] [Related]
18. Fluctuation of lacosamide serum concentrations during the day and occurrence of adverse drug reactions--first clinical experience.
Sattler A; Schaefer M; May TW; Rambeck B; Brandt C
Epilepsy Res; 2011 Aug; 95(3):207-12. PubMed ID: 21543186
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive lacosamide--5 years' clinical experience.
Stephen LJ; Kelly K; Parker P; Brodie MJ
Epilepsy Res; 2014 Oct; 108(8):1385-91. PubMed ID: 25064538
[TBL] [Abstract][Full Text] [Related]
20. Lacosamide use in children with epilepsy: Retention rate and effect of concomitant sodium channel blockers in a large cohort.
McGinnis E; Kessler SK
Epilepsia; 2016 Sep; 57(9):1416-25. PubMed ID: 27430392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
